Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Uwe Reusch"'
Autor:
Uwe Reusch, Joachim Koch, Sheena Pinto, Susanne Wingert, Jens Pahl, Armin Beez, Sabrina Purr, Arndt Schottelius
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/6e5e4f7765b34750811e4f80882b6f79
Autor:
Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Michael Kluge, Michael Damrat, Jens Pahl, Ute Schniegler-Mattox, Thomas Mueller, Ivica Fucek, Kristina Ellwanger, Michael Tesar, Torsten Haneke, Joachim Koch, Martin Treder, Wolfgang Fischer, Erich Rajkovic
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Epidermal growth factor receptor (EGFR)-targeted cancer therapy such as anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors have demonstrated clinical efficacy. However, there remains a medical need addressing limitations of these therapie
Externí odkaz:
https://doaj.org/article/4d63d162888a47209f9f61da3778fcae
Autor:
Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Thomas Müller, Ute Schniegler-Mattox, Joachim Koch, Michael Tesar
Publikováno v:
Antibodies, Vol 11, Iss 1, p 12 (2022)
Innate cell engager (ICE®) constructs are bispecific tetravalent antibodies targeting specific tumor antigens and simultaneously engaging natural killer (NK) cell and macrophage receptors for the destruction of tumor cells. Pre-complexing of ICE® c
Externí odkaz:
https://doaj.org/article/c2ab650ca3c04175a6acf0e1b84c5100
Autor:
Kristina Ellwanger, Uwe Reusch, Ivica Fucek, Stefan Knackmuss, Michael Weichel, Thorsten Gantke, Vera Molkenthin, Eugene A. Zhukovsky, Michael Tesar, Martin Treder
Publikováno v:
Frontiers in Oncology, Vol 7 (2017)
To harness the cytotoxic capacity of immune cells for the treatment of solid tumors, we developed tetravalent, bispecific tandem diabody (TandAb) antibodies that recognize EGFRvIII, the deletion variant III of the epidermal growth factor receptor (EG
Externí odkaz:
https://doaj.org/article/251deeb0b6f541bf8a55fb908e37055d
Autor:
Kerrilyn Naidoo, Sibusiso T Malindisa, Tyrone C Otgaar, Martin Bernert, Bianca Da Costa Dias, Eloise Ferreira, Uwe Reusch, Stefan Knackmuss, Melvyn Little, Stefan F T Weiss, Boitelo T Letsolo
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0141618 (2015)
Cancer has become a major problem worldwide due to its increasing incidence and mortality rates. Both the 37kDa/67kDa laminin receptor (LRP/LR) and telomerase are overexpressed in cancer cells. LRP/LR enhances the invasiveness of cancer cells thereby
Externí odkaz:
https://doaj.org/article/9511088401f7480fba48e10fafe0c834
Autor:
Carryn Chetty, Thandokuhle Khumalo, Bianca Da Costa Dias, Uwe Reusch, Stefan Knackmuss, Melvyn Little, Stefan F T Weiss
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e96268 (2014)
Two key events, namely adhesion and invasion, are pivotal to the occurrence of metastasis. Importantly, the 37 kDa/67 kDa laminin receptor (LRP/LR) has been implicated in enhancing these two events thus facilitating cancer progression. In the current
Externí odkaz:
https://doaj.org/article/bdbf3ea3158c47489cd2da5a661970a7
Autor:
Thandokuhle Khumalo, Uwe Reusch, Stefan Knackmuss, Melvyn Little, Robin B Veale, Stefan F T Weiss
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e66297 (2013)
Adhesion and invasion have been identified as the two key components of metastasis. The 37 kDa/67 kDa laminin receptor (LRP/LR) is thought to enhance these two processes thus endorsing the progression of cancer. Here we report on LRP/LR and the metas
Externí odkaz:
https://doaj.org/article/fd6ff9937c3c499292bef26692859e76
In vitro inhibition of angiogenesis by antibodies directed against the 37kDa/67kDa laminin receptor.
Autor:
Raksha Khusal, Bianca Da Costa Dias, Kiashanee Moodley, Clement Penny, Uwe Reusch, Stefan Knackmuss, Melvyn Little, Stefan F T Weiss
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e58888 (2013)
The 37kDa/67kDa laminin receptor (LRP/LR) is a central receptor mediating interactions between tumour cells and the basement membrane and is thereby a key player in adhesion and invasion, essential processes in metastatic cancer. To affect continued
Externí odkaz:
https://doaj.org/article/bf210c9bac8743388058c2d7e3807b0c
Autor:
Adelheid Cerwenka, Martin Treder, Erich Rajkovic, Thorsten Gantke, Uwe Reusch, Annette Arnold, Jana-Julia Götz, Joachim Koch, Jens H.W. Pahl
CD16A is a potent cytotoxicity receptor on human natural killer (NK) cells, which can be exploited by therapeutic bispecific antibodies. So far, the effects of CD16A-mediated activation on NK cell effector functions beyond classical antibody-dependen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae3f8cbb51f9ad2483ec37cb1332000a
https://doi.org/10.1158/2326-6066.c.6548009.v1
https://doi.org/10.1158/2326-6066.c.6548009.v1
Autor:
Adelheid Cerwenka, Martin Treder, Erich Rajkovic, Thorsten Gantke, Uwe Reusch, Annette Arnold, Jana-Julia Götz, Joachim Koch, Jens H.W. Pahl
S1. NK cell cytotoxicity and IFNγ are enhanced by AFM13 towards different types of lymphoma cells. S2. Pre-activation by rituximab increases IL2-dependent NK cell proliferation and expansion. S3. Recovery of NK cell function by IL2 or IL15 after AFM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::386c564d785a74356393fe303d26f420
https://doi.org/10.1158/2326-6066.22535999.v1
https://doi.org/10.1158/2326-6066.22535999.v1